Medtronic plc
MDT · NYSE
Company research
Medtronic plc (NYSE: MDT) is the world's largest standalone medical technology company, founded in 1949 and headquartered in Galway, Ireland, with approximately 95,000 employees and a market capitalization of approximately $108 billion. The company develops, manufactures, and sells a broad range of device-based medical therapies across four core segments — Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio, and Diabetes Operating Unit — serving healthcare systems, clinicians, and patients across 150+ countries. Its product portfolio spans implantable pacemakers and defibrillators, transcatheter heart valves, surgical robotics, AI-powered endoscopy platforms, spinal fixation devices, neurovascular products, insulin pumps, and continuous glucose monitoring systems, among others, treating approximately 70 health conditions and reaching over 75 million patients annually. With approximately $32.4 billion in FY2024 revenue, more than 70,000 patents, and a strategic focus on high-growth platforms such as pulsed field ablation, robotic surgery, and automated insulin delivery, Medtronic continues to leverage its global scale and R&D depth to maintain a leading competitive position in the medical devices industry.
Research reports
DBS Bank (DBS Group Research, US Equity Research) · March 27, 2026Medtronic PLC – Earning in-line with guidance, insulin pump headwinds still persevere
DBS reiterates a HOLD rating with a USD 90 target price, noting Q3 FY26 revenue and EPS in line with guidance and strong growth from the cardiovascular portfolio driven by pulsed field ablation, while highlighting margin resilience, dividend support and major risks from GLP‑1 drugs potentially eroding up to half of insulin pump sales and pricing/competitive pressures in China.
Sure Dividend · February 17, 2026Medtronic plc (MDT)Sure Dividend assigns a Hold rating, projecting roughly 8.3% annual total return over five years based on 6% expected EPS growth, a near‑3% dividend yield and a slightly negative valuation effect, emphasizing Medtronic’s strong dividend growth record and healthcare tailwinds but noting modest historical earnings growth, inflation and supply chain headwinds, and a rising payout ratio as constraints.
Zacks Investment Research · January 7, 2026Zacks Equity Research Report for MDTZacks maintains a Neutral recommendation with a USD 105 6–12 month price target, arguing that Medtronic is well positioned in several growth markets including cardiac ablation, neuromodulation and renal denervation, supported by strong CAS share gains and emerging Symplicity hypertension opportunity, while flagging tariff and FX headwinds, macro uncertainties, elevated cost pressures and a competitive landscape as key risks to margins and growth.
Sure Dividend · September 3, 2025Medtronic plc (MDT)This Sure Dividend report rates MDT a Buy, estimating about 9.2% annual total return driven by 6% projected EPS growth, a ~3% dividend yield and a small valuation tailwind, highlighting Medtronic’s high-quality medical device franchise, long dividend growth streak, resilient performance through recent macro headwinds, and strong balance sheet, while cautioning that past earnings growth has been modest and that cost inflation and supply chains remain important watchpoints.